#	Pagina
attuale pagina	/open-h2020/projects/195998/index.html

Opendata, web and dolomites

MINERVA SIGNED

Micro-RNAs of neutrophils in renal ANCA-associated vasculitis

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

MINERVA project word cloud

Explore the words cloud of the MINERVA project. It provides you a very rough idea of what is the project "MINERVA" about.

cytoplasm requiring dialysis critical anca first activated tools renal damage correlated cell ec arrays transfer diseases severity disease accumulating deregulated biomarkers evolve plasma regarding pave patients intracellular shown 25 secreted urine induce vitro translational vasculitis revealed activation subsequent samples anti microparticles released mirna therapeutic options regulation assays crosstalks date outcome virtually types neutrophils taqman pathophysiology antibodies treatment indicate function data transplantation exposed unexplored stimulated functional neutrophil endothelial density mirnas angiogenesis biological release aav stage expression

Project "MINERVA" data sheet

The following table provides information about the project.

Coordinator	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Organization address address: RUE DE TOLBIAC 101 city: PARIS postcode: 75654 website: www.inserm.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Total cost	173˙076 €
EC max contribution	173˙076 € (100%)
Programme	1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
Code Call	H2020-MSCA-IF-2014
Funding Scheme	MSCA-IF-EF-ST
Starting year	2016
Duration (year-month-day)	from 2016-04-01 to 2018-03-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Organization address address: RUE DE TOLBIAC 101 city: PARIS postcode: 75654 website: www.inserm.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	coordinator	173˙076.00

Map

Project objective

Activation of neutrophils by ANCA (“Anti-Neutrophil Cytoplasm Antibodies”) and subsequent endothelial cell (EC) damage is the main feature of ANCA-associated vasculitis (AAV). There is no specific treatment for AAV to date and 25% of patients evolve towards end-stage renal disease requiring dialysis and renal transplantation. While accumulating data indicate that miRNAs control major biological responses in various cell types including EC and neutrophils and are involved in the pathophysiology of several diseases, their role in AAV has been virtually unexplored. In addition, recent studies have shown that ANCA-activated neutrophils can induce EC damage through the release of microparticles, but while many studies have revealed a critical role for miRNAs secreted within microparticles in intracellular crosstalks, there is no data so far on the role of miRNAs in this process. Here, we propose to identify miRNAs deregulated in neutrophils exposed to ANCA and released in microparticles that promote EC damage in AAV. These miRNAs will be identified using TaqMan Low Density Arrays in ANCA-stimulated neutrophils in vitro and in the microparticles they release, as well as in neutrophils from patients with AAV. To assess whether these miRNAs could be used as biomarkers, their expression will also be analyzed in plasma and urine samples from AAV patients, and correlated with severity and outcome of the disease. The transfer of neutrophil-secreted miRNAs to EC will be assessed in vitro, and the function of these miRNAs in the regulation of EC responses (activation, angiogenesis) will be studied in various functional assays. While miRNAs are emerging as new therapeutic tools for several diseases, this translational study will provide the first data regarding the expression and function of neutrophil miRNAs in AAV and may therefore pave the way for novel promising miRNA-based therapeutic options in these patients.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MINERVA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MINERVA" are provided by the European Opendata Portal: CORDIS opendata.